CardiovascularIn Clinical Trials

Ularitide (Urodilatin)

Intravenous

Overview

Ularitide is a synthetic 32-amino acid peptide analogue of urodilatin, a natriuretic peptide produced in renal tubular cells. It binds to guanylyl cyclase A receptors to increase cyclic GMP, resulting in vasodilation, enhanced sodium excretion, and suppression of the renin-angiotensin-aldosterone system.

Mechanism of Action

The peptide was developed for treatment of acute decompensated heart failure with the goal of improving renal function and hemodynamics..

Research Summary & Key Findings

The TRUE-AHF trial (European Heart Journal, 2017) evaluated ularitide in over 2,000 patients with acute heart failure but did not meet its primary endpoint of cardiovascular mortality reduction. Despite promising earlier phase 2 data showing hemodynamic benefits, regulatory approval was not pursued following the neutral phase 3 results.

Clinical Status

In Clinical Trials

Ularitide (Urodilatin) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Ularitide (Urodilatin) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Ularitide (Urodilatin).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.